1. Home
  2. NVAX

NVAX

Novavax Inc.

Logo Novavax Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Founded: 1987 Country:
United States
United States
Employees: 1992 City: GAITHERSBURG
Market Cap: 555.6M IPO Year: 1995
Target Price: $17.00 AVG Volume (30 days): 7.4M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -5.41 EPS Growth: N/A
52 Week Low/High: $3.53 - $11.36 Next Earning Date: 05-07-2024
Revenue: $983,705,000 Revenue Growth: -50.36%
Revenue Growth (this year): -11.9% Revenue Growth (next year): 9.36%

Share on Social Networks: